{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:43:41Z","timestamp":1793580221498,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>AZD0156 is an oral inhibitor of ATM, a serine threonine kinase that plays a key role in DNA damage response (DDR) associated with double-strand breaks. Topoisomerase-I inhibitor irinotecan is used clinically to treat colorectal cancer (CRC), often in combination with 5-fluorouracil (5FU). AZD0156 in combination with irinotecan and 5FU was evaluated in preclinical models of CRC to determine whether low doses of AZD0156 enhance the cytotoxicity of irinotecan in chemotherapy regimens used in the clinic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Anti-proliferative effects of single-agent AZD0156, the active metabolite of irinotecan (SN38), and combination therapy were evaluated in 12 CRC cell lines. Additional assessment with clonogenic assay, cell cycle analysis, and immunoblotting were performed in 4 selected cell lines. Four colorectal cancer patient derived xenograft (PDX) models were treated with AZD0156, irinotecan, or 5FU alone and in combination for assessment of tumor growth inhibition (TGI). Immunofluorescence was performed on tumor tissues. The DDR mutation profile was compared across <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Enhanced effects on cellular proliferation and regrowth were observed with the combination of AZD0156 and SN38 in select models. In cell cycle analysis of these models, increased G2\/M arrest was observed with combination treatment over either single agent. Immunoblotting results suggest an increase in DDR associated with irinotecan therapy, with a reduced effect noted when combined with AZD0156, which is more pronounced in some models. Increased TGI was observed with the combination of AZD0156 and irinotecan as compared to single-agent therapy in some PDX models. The DDR mutation profile was variable across models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>AZD0156 and irinotecan provide a rational and active combination in preclinical colorectal cancer models. Variability across in vivo and in vitro results may be related to the variable DDR mutation profiles of the models evaluated. Further understanding of the implications of individual DDR mutation profiles may help better identify patients more likely to benefit from treatment with the combination of AZD0156 and irinotecan in the clinical setting.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10084-7","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T10:15:04Z","timestamp":1667038504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-9481","authenticated-orcid":false,"given":"S. Lindsey","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey M.","family":"Bagby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Schlaepfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betelehem W.","family":"Yacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis M.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Lieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis D.","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine B.","family":"Cadogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth D.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Durant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wells A.","family":"Messersmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Pitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"10084_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","volume":"149","author":"AM Weber","year":"2015","unstructured":"Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol Ther. 2015;149:124\u201338.","journal-title":"Pharmacol Ther"},{"key":"10084_CR2","doi-asserted-by":"publisher","unstructured":"Gourley C, Balmana J, Ledermann JA, Serra V, Dent R, Loibl S, Pujade-Lauraine E, Boulton SJ. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. J Clin Oncol. 2019. https:\/\/doi.org\/10.1200\/JCO.18.02050.","DOI":"10.1200\/JCO.18.02050"},{"key":"10084_CR3","doi-asserted-by":"publisher","first-page":"107391","DOI":"10.1016\/j.pharmthera.2019.07.002","volume":"203","author":"MH Jin","year":"2019","unstructured":"Jin MH, Oh DY. ATM in DNA repair in cancer. Pharmacol Ther. 2019;203:107391.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10084_CR4","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","volume":"61","author":"KG Pike","year":"2018","unstructured":"Pike KG, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N, Davies NL, de-Almeida C, Degorce SL, Didelot M, et al. The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one). J Med Chem. 2018;61(9):3823\u201341.","journal-title":"J Med Chem"},{"issue":"1","key":"10084_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","volume":"19","author":"LC Riches","year":"2020","unstructured":"Riches LC, Trinidad AG, Hughes G, Jones GN, Hughes AM, Thomason AG, Gavine P, Cui A, Ling S, Stott J, et al. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically. Mol Cancer Ther. 2020;19(1):13\u201325.","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"10084_CR6","first-page":"5077","volume":"49","author":"YH Hsiang","year":"1989","unstructured":"Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Can Res. 1989;49(18):5077\u201382.","journal-title":"Can Res"},{"issue":"4","key":"10084_CR7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1124\/mol.61.4.742","volume":"61","author":"J Wu","year":"2002","unstructured":"Wu J, Yin MB, Hapke G, Toth K, Rustum YM. Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin. Mol Pharmacol. 2002;61(4):742\u20138.","journal-title":"Mol Pharmacol"},{"issue":"9","key":"10084_CR8","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.3390\/cells9092012","volume":"9","author":"C Dobler","year":"2020","unstructured":"Dobler C, Jost T, Hecht M, Fietkau R, Distel L. Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells. Cells. 2020;9(9):2012.","journal-title":"Cells"},{"issue":"22","key":"10084_CR9","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1158\/1078-0432.CCR-10-2054","volume":"16","author":"SA Flanigan","year":"2010","unstructured":"Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S. The insulin-like growth factor I receptor\/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin Cancer Res. 2010;16(22):5436\u201346.","journal-title":"Clin Cancer Res"},{"key":"10084_CR10","doi-asserted-by":"publisher","first-page":"642328","DOI":"10.3389\/fonc.2021.642328","volume":"11","author":"SJ Hartman","year":"2021","unstructured":"Hartman SJ, Bagby SM, Yacob BW, Simmons DM, MacBeth M, Lieu CH, Davis SL, Leal AD, Tentler JJ, Diamond JR, et al. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Front Oncol. 2021;11:642328.","journal-title":"Front Oncol"},{"issue":"11","key":"10084_CR11","doi-asserted-by":"publisher","first-page":"e113037","DOI":"10.1371\/journal.pone.0113037","volume":"9","author":"TM Pitts","year":"2014","unstructured":"Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, et al. Dual pharmacological targeting of the MAP kinase and PI3K\/mTOR pathway in preclinical models of colorectal cancer. PLoS One. 2014;9(11):e113037.","journal-title":"PLoS One"},{"issue":"11","key":"10084_CR12","doi-asserted-by":"publisher","first-page":"e0224137","DOI":"10.1371\/journal.pone.0224137","volume":"14","author":"E Demidenko","year":"2019","unstructured":"Demidenko E, Miller TW. Statistical determination of synergy based on Bliss definition of drugs independence. PLoS One. 2019;14(11):e0224137.","journal-title":"PLoS One"},{"issue":"2","key":"10084_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/19466315.2018.1437071","volume":"10","author":"Q Liu","year":"2018","unstructured":"Liu Q, Yin X, Languino LR, Altieri DC. Evaluation of drug combination effect using a Bliss independence dose-response surface model. Stat Biopharm Res. 2018;10(2):112\u201322.","journal-title":"Stat Biopharm Res"},{"key":"10084_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fonc.2018.00245","volume":"8","author":"H Hafsi","year":"2018","unstructured":"Hafsi H, Dillon MT, Barker HE, Kyula JN, Schick U, Paget JT, Smith HG, Pedersen M, McLaughlin M, Harrington KJ. Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status. Front Oncol. 2018;8:245.","journal-title":"Front Oncol"},{"key":"10084_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fonc.2020.00127","volume":"10","author":"MI Carr","year":"2020","unstructured":"Carr MI, Zimmermann A, Chiu LY, Zenke FT, Blaukat A, Vassilev LT. DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia. Front Oncol. 2020;10:127.","journal-title":"Front Oncol"},{"issue":"10","key":"10084_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1530\/ERC-19-0262","volume":"26","author":"A Kar","year":"2019","unstructured":"Kar A, Zhang Y, Yacob BW, Saeed J, Tompkins KD, Bagby SM, Pitts TM, Somerset H, Leong S, Wierman ME, et al. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC. Endocr Relat Cancer. 2019;26(10):765\u201378.","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10084_CR17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/CAD.0000000000000673","volume":"29","author":"A Capasso","year":"2018","unstructured":"Capasso A, Pitts TM, Klauck PJ, Bagby SM, Westbrook L, Kaplan J, Soleimani M, Spreafico A, Tentler JJ, Diamond JR, et al. Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. Anticancer Drugs. 2018;29(9):827\u201338.","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10084_CR18","doi-asserted-by":"publisher","first-page":"e58089","DOI":"10.1371\/journal.pone.0058089","volume":"8","author":"EL Bradshaw-Pierce","year":"2013","unstructured":"Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD. Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One. 2013;8(3):e58089.","journal-title":"PLoS One"},{"issue":"3","key":"10084_CR19","doi-asserted-by":"publisher","first-page":"e92444","DOI":"10.1371\/journal.pone.0092444","volume":"9","author":"C Guzman","year":"2014","unstructured":"Guzman C, Bagga M, Kaur A, Westermarck J, Abankwa D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS One. 2014;9(3):e92444.","journal-title":"PLoS One"},{"issue":"1","key":"10084_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12885-018-4036-z","volume":"18","author":"PJ Klauck","year":"2018","unstructured":"Klauck PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, Selby HM, Spreafico A, Tentler JJ, Tan AC, Kim J, Arcaroli JJ, et al. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. BMC Cancer. 2018;18(1):136.","journal-title":"BMC Cancer"},{"issue":"67","key":"10084_CR21","doi-asserted-by":"publisher","first-page":"110904","DOI":"10.18632\/oncotarget.22920","volume":"8","author":"J Greene","year":"2017","unstructured":"Greene J, Nguyen A, Bagby SM, Jones GN, Tai WM, Quackenbush KS, Schreiber A, Messersmith WA, Devaraj KM, Blatchford P, et al. The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy. Oncotarget. 2017;8(67):110904\u201313.","journal-title":"Oncotarget"},{"key":"10084_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fonc.2017.00094","volume":"7","author":"AA Ionkina","year":"2017","unstructured":"Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, et al. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. Front Oncol. 2017;7:94.","journal-title":"Front Oncol"},{"key":"10084_CR23","unstructured":"Cancer Cell Line Encyclopedia. In: The Broad Institute of MIT and Harvard.\u00a0https:\/\/sites.broadinstitute.org\/ccle\/."},{"issue":"19","key":"10084_CR24","doi-asserted-by":"publisher","first-page":"28273","DOI":"10.18632\/oncotarget.8626","volume":"7","author":"KS Quackenbush","year":"2016","unstructured":"Quackenbush KS, Bagby S, Tai WM, Messersmith WA, Schreiber A, Greene J, Kim J, Wang G, Purkey A, Pitts TM, et al. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Oncotarget. 2016;7(19):28273\u201385.","journal-title":"Oncotarget"},{"key":"10084_CR25","first-page":"1298","volume":"2004","author":"SMJ Arnould","year":"2004","unstructured":"Arnould SMJ, Thurston DE, Jodrell DI, Guichard SM. Impact on the cell cycle and involvement of ATM, ATR, chk1 and chk2 kinases in the cytotoxicity of SJG-136, a new pyrrolobenzodiazepine dimer. Cancer Res. 2004;2004:1298.","journal-title":"Cancer Res"},{"key":"10084_CR26","doi-asserted-by":"publisher","first-page":"607282","DOI":"10.3389\/fimmu.2021.607282","volume":"12","author":"JA Marin-Jimenez","year":"2021","unstructured":"Marin-Jimenez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, et al. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Front Immunol. 2021;12:607282.","journal-title":"Front Immunol"},{"issue":"10","key":"10084_CR27","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41416-018-0286-4","volume":"119","author":"GN Jones","year":"2018","unstructured":"Jones GN, Rooney C, Griffin N, Roudier M, Young LA, Garcia-Trinidad A, Hughes GD, Whiteaker JR, Wilson Z, Odedra R, et al. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry. Br J Cancer. 2018;119(10):1233\u201343.","journal-title":"Br J Cancer"},{"issue":"3","key":"10084_CR28","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s10637-010-9626-9","volume":"30","author":"D Davidson","year":"2012","unstructured":"Davidson D, Coulombe Y, Martinez-Marignac VL, Amrein L, Grenier J, Hodkinson K, Masson JY, Aloyz R, Panasci L. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest New Drugs. 2012;30(3):1248\u201356.","journal-title":"Invest New Drugs"},{"issue":"6","key":"10084_CR29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/jmcb\/mju045","volume":"6","author":"L Zannini","year":"2014","unstructured":"Zannini L, Delia D, Buscemi G. CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol. 2014;6(6):442\u201357.","journal-title":"J Mol Cell Biol"},{"issue":"5","key":"10084_CR30","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.celrep.2018.06.064","volume":"24","author":"M Sasaki","year":"2018","unstructured":"Sasaki M, Terabayashi T, Weiss SM, Ferby I. The Tumor Suppressor MIG6 Controls Mitotic Progression and the G2\/M DNA Damage Checkpoint by Stabilizing the WEE1 Kinase. Cell Rep. 2018;24(5):1278\u201389.","journal-title":"Cell Rep"},{"issue":"6","key":"10084_CR31","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/1535-7163.MCT-12-0707","volume":"12","author":"MA Batey","year":"2013","unstructured":"Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NM, Lau A, Newell DR, Curtin NJ. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Mol Cancer Ther. 2013;12(6):959\u201367.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10084_CR32","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-12-3408","volume":"19","author":"L Biddlestone-Thorpe","year":"2013","unstructured":"Biddlestone-Thorpe L, Sajjad M, Rosenberg E, Beckta JM, Valerie NC, Tokarz M, Adams BR, Wagner AF, Khalil A, Gilfor D, et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res. 2013;19(12):3189\u2013200.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10084_CR33","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo J, Lord CJ, Serra V, Tutt A, Balmana J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30(9):1437\u201347.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10084-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T22:03:59Z","timestamp":1667081039000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10084-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10084"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10084-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]},"assertion":[{"value":"4 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies were performed in a facility accredited by the American Association for Accreditation of Laboratory Animal Care in accordance with NIH guidelines and approved by the University of Colorado Institutional Animal Care and Use Committee prior to initiation (IACUC number 021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SLD served as a local Principal Investigator on the AZ AToM clinical trial (NCT02588105), with funding support provided to the University of Colorado Cancer Center for these efforts. TP received grant funding from AstraZeneca for this project. EC, GH, and SD are employees of AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1107"}}